Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - dl-alpha-tocopherol, quantity: 0.64 mg/ml; retinol palmitate, quantity: 135.3 microgram/ml; phytomenadione, quantity: 20 microgram/ml; ergocalciferol, quantity: 1 microgram/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; glycerol; egg lecithin; soya oil - vitalipid n infant is indicated as a supplement in complete intravenous nutrition to meet the daily requirements of the fat- soluble vitamins a, d2, e and k1 in paediatric patients up to 11 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - phytomenadione, quantity: 15 microgram/ml; ergocalciferol, quantity: 0.5 microgram/ml; retinol palmitate, quantity: 194.1 microgram/ml; dl-alpha-tocopherol, quantity: 0.91 mg/ml - injection, concentrated - excipient ingredients: soya oil; egg lecithin; glycerol; water for injections; sodium hydroxide - vitalipid n adult is indicated as a supplement in complete intravenous nutrition to meet the daily requirements of the fat- soluble vitamins a, d2, e and k1.

Israel - English - Ministry of Health

cure medical & technical supply - ergocalciferol; phytomenadione; retinol palmitate; tocopherol - concentrate for solution for infusion - phytomenadione 15 mcg/ml; ergocalciferol 0.5 mcg/ml; tocopherol 0.91 mg/ml; retinol palmitate 194.1 mcg/ml - combinations - combinations - vitalipid n adult is indicated in adult and children above 11 years of age as a supplement in iv nutrition to meet the daily requirement of the fat soluble vitamins a, d2, e,k1.

Israel - English - Ministry of Health

cure medical & technical supply - ergocalciferol; phytomenadione; retinol palmitate; tocopherol - concentrate for solution for infusion - phytomenadione 20 mcg/ml; ergocalciferol 1 mcg/ml; tocopherol 0.64 mg/ml; retinol palmitate 135.3 mcg/ml - combinations of electrolytes - combinations of electrolytes - vitalipid n infants is indicated in infants and children up to 11 years of age as a supplement in iv nutrition to meet the daily requirement of the fat soluble vitamins a, d2, e,k1.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - dl-alpha tocopherol 0.91 mg/ml;  ; ergocalciferol 0.5 µg/ml; phytomenadione 15 µg/ml; retinol palmitate 194.1 µg/ml (corresponding to 99 ug retinol) - emulsion for injection - active: dl-alpha tocopherol 0.91 mg/ml   ergocalciferol 0.5 µg/ml phytomenadione 15 µg/ml retinol palmitate 194.1 µg/ml (corresponding to 99 ug retinol) excipient: egg lecithin glycerol sodium hydroxide soya oil water for injection - vitalipid n adult is indicated as a supplement in complete intravenous nutrition to meet the daily requirements of the fat-soluble vitamins a, d2, e and k1.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - dl-alpha tocopherol 0.64 mg/ml;  ; ergocalciferol 1 µg/ml; phytomenadione 20 µg/ml; retinol palmitate 135.3 µg/ml (corresponding to 69 ug retinol) - emulsion for injection - active: dl-alpha tocopherol 0.64 mg/ml   ergocalciferol 1 µg/ml phytomenadione 20 µg/ml retinol palmitate 135.3 µg/ml (corresponding to 69 ug retinol) excipient: egg lecithin glycerol sodium hydroxide soya oil water for injection - vitalipid n infant is indicated in paediatric patients up to 11 years of age as a supplement in complete intravenous nutrition to meet the daily requirements of the fat-soluble vitamins a, d2, e and k1.

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - retinol palmitate ; ergocalciferol ; dl-alfa-tocoferol ; phytomenadione - concentrate for susp for inf - 10 millilitre - vitamins

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - chromic chloride hexahydrate, quantity: 5.33 microgram/ml; ferric chloride hexahydrate, quantity: 540 microgram/ml; sodium selenite, quantity: 17.29 microgram/ml; sodium fluoride, quantity: 210 microgram/ml; cupric chloride dihydrate, quantity: 102.3 microgram/ml; potassium iodide, quantity: 16.6 microgram/ml; sodium molybdate dihydrate, quantity: 4.85 microgram/ml; manganese chloride tetrahydrate, quantity: 19.79 microgram/ml; zinc chloride, quantity: 1.05 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; xylitol - to meet basal to moderately increased requirements of trace elements in parenteral nutrition in adults, when either oral or enteral nutrition is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - sodium glycerophosphate hydrate, quantity: 6.122 g (equivalent: sodium glycerophosphate, qty 4.32 g) - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections - glycophos? is indicated in adult and paediatric patients as a supplement to parenteral nutrition to meet the daily requirements of phosphate.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - sodium glycerophosphate pentahydrate 306.1 mg/ml (corresponds to sodium glycerophosphate anhydrous 216 mg/ml - ) - concentrate for infusion - 306.1 mg/ml - active: sodium glycerophosphate pentahydrate 306.1 mg/ml (corresponds to sodium glycerophosphate anhydrous 216 mg/ml - ) excipient: hydrochloric acid water for injection - glycophos is indicated in adult patients, children, infants and neonates as a supplement in intravenous nutrition to meet the requirement of phosphate.